# Regeneron Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Regeneron Pharmaceuticals, Inc). ## Overview Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Its business combines internal research, clinical development, biologics manufacturing, and product commercialization, with a portfolio that includes marketed therapies and a pipeline of product candidates. ## Products & services • EYLEA HD and EYLEA ophthalmology medicines • Dupixent collaboration revenue and related commercialization • Libtayo oncology medicine • Praluent cholesterol-lowering therapy • Kevzara and other partnered biologics • Clinical-stage product candidates and new indications - **Ophthalmology** (45%) — Retinal disease medicines, including EYLEA HD and EYLEA, used in eye care indications. - **Immunology / Inflammation** (30%) — Partnered and co-commercialized therapies such as Dupixent and Kevzara for immune-mediated diseases. - **Oncology** (10%) — Cancer therapies including Libtayo and related oncology development programs. - **Cardiometabolic** (5%) — Lipid-lowering and cardiovascular-related products such as Praluent. - **Collaboration and other revenue** (10%) — Profit-sharing, royalties, and manufacturing reimbursement from partners such as Sanofi and Bayer. - EYLEA HD and EYLEA ophthalmology medicines - Dupixent collaboration revenue and related commercialization - Libtayo oncology medicine - Praluent cholesterol-lowering therapy - Kevzara and other partnered biologics - Clinical-stage product candidates and new indications ## Customers Regeneron sells primarily to distributor customers, specialty pharmacies, and healthcare providers through the U.S. pharmaceutical distribution channel. A large portion of gross product revenue is concentrated in two distributor customers, while some products are commercialized globally through partners such as Sanofi and Bayer. Demand is ultimately driven by physicians, hospitals, and specialty care settings treating serious chronic and acute diseases. - **Distributor customers** (primary) — Large U.S. distributors and specialty pharmacies buy product inventory and resell to providers and pharmacies. - **Healthcare providers** (primary) — Physicians, clinics, and hospitals prescribe and administer Regeneron's medicines to patients. - **Pharmacy and specialty pharmacy channel** (secondary) — Specialty pharmacies handle distribution for biologics and other specialty medicines. - **Collaborators and license partners** (primary) — Partners such as Sanofi and Bayer commercialize certain products and share profits or royalties. - **Third-party payors** (primary) — Private insurers and government programs determine coverage and reimbursement access. - Two large distributor customers account for most gross product revenue - Specialty pharmacies distribute products to healthcare providers - Physicians and hospitals are the end users for prescribed therapies - Partners such as Sanofi and Bayer commercialize selected products - Payers influence access through reimbursement and coverage decisions ## Geography Regeneron is headquartered in the United States and records net product sales in the U.S. through distributor and specialty pharmacy channels. Outside the United States, key products are commercialized through partners such as Bayer and Sanofi, which creates meaningful international exposure even when Regeneron does not book direct product sales in those markets. - United States is the core market for direct product sales - Bayer records sales of EYLEA outside the United States - Sanofi records global sales of Dupixent and Kevzara - International exposure is often partnership-based rather than direct - U.S. reimbursement policy strongly affects commercial performance ## Strategy Regeneron's strategy centers on internal discovery, clinical development, and commercialization of biologic medicines for serious diseases, supported by a large pipeline of homegrown candidates. It also relies on collaborations to extend reach, share development/commercialization economics, and support global product access for selected therapies. - **Grow the marketed portfolio** (short-term) — Commercial success of EYLEA HD, EYLEA, and Dupixent is central to the business model. - **Advance the pipeline** (medium-term) — A large internal pipeline is needed to replenish and diversify future revenue sources. - **Strengthen manufacturing and supply** (medium-term) — Biologics require reliable production, fill/finish, and distribution capacity. - **Maintain collaboration economics** (medium-term) — Partnered products contribute profit share, royalties, and manufacturing reimbursement. - Advance internally discovered product candidates through clinical trials - Protect and extend market position of key marketed products - Use collaborations to commercialize products globally - Expand approved indications for existing medicines - Scale manufacturing and fill-finish capabilities for biologics ## Risks Regeneron depends heavily on a small number of marketed products and on reimbursement access, so commercial concentration can quickly affect results. The company also faces typical biotech risks around clinical failure, regulatory delay, patent loss, biosimilar competition, and manufacturing complexity, all of which can reduce exclusivity or interrupt supply. - **Product concentration** [high] — A large share of revenue depends on a few marketed therapies. - **Distributor customer concentration** [high] — Two customers account for most gross product revenue, creating channel risk. - **Reimbursement and pricing pressure** [high] — Payor coverage and copay support determine patient access and net sales. - **Biosimilar and competitive erosion** [high] — Competing products can be more cost effective or easier to administer. - **Regulatory and development failure** [high] — Drug development is costly, uncertain, and subject to approval risk. - **Manufacturing and supply chain disruption** [medium] — Biologics require complex production, fill/finish, and distribution steps. - Heavy dependence on EYLEA, EYLEA HD, and Dupixent - Two distributor customers represent concentrated revenue exposure - Coverage and reimbursement changes can reduce product access - Biosimilars and competing drugs can erode market share - Clinical, regulatory, and manufacturing setbacks can delay launches ## Accounting Regeneron's reported results are shaped by collaboration accounting, especially profit share and reimbursement from Sanofi and Bayer, which can move with partner sales and manufacturing activity. Product revenue also depends on estimates tied to distributor sell-through, rebates, returns, and reimbursement, while pipeline and exclusivity risks can create impairment or reserve considerations if programs underperform. - **Collaboration revenue recognition** — Affects collaboration revenue and comparability across periods - **Net product sales estimates** — Affects reported product revenue and margins - **Distributor concentration and receivables** — Affects credit loss exposure and revenue timing - **Clinical and intangible asset judgments** — Affects asset values and future expense recognition - Collaboration revenue depends on partner sales and profit-sharing formulas - Distributor concentration affects revenue timing and receivable exposure - Rebates, returns, and copay support require estimation in net product sales - Manufacturing reimbursement is recorded with collaboration revenue - Clinical and patent outcomes can affect impairment and reserve judgments --- *Last updated: 2026-09-24T11:37:43.444492+00:00*